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???LIPOXIN-A4 IN ????RABBIT MODEL OF ATHEROSCLEROSIS AND  
??????STEATO?IS   
 
JASKAMAL SINGH 
ABSTRACT 
 
Background  
Obesity is a global health problem that is associated with wide range of diseases, 
including atherosclerosis and Nonalcoholic fatty liver (NAFL) disease. Hepatic 
inflammation can cause cirrhosis, hepatic decompensation (liver failure) and cancer. 
Recent research now looks at the chronic systemic effects and inter-organ communication 
between atherosclerosis potentially promoting the development of NAFL. The resolution 
of inflammation is regulated naturally in the body by specialized pro-resolving mediators 
(SPMs). Immunoresolvents like ⍹6-derived Lipoxin A4 are suggested as a therapeutic 
strategy to overcome chronic inflammation and disease. In this study we investigated the 
therapeutic potential of Lipoxin A4 (LXA4) in cholesterol fed rabbit model of 
hypercholesterolemia, with atherosclerotic plaques and confined vascular endothelial 
injury and its effect on the progression of NAFL. 
 
Objective  
This is a continuation of studies pioneered in the Hamilton lab and an extension of the 
recent study by Taylor et. al in 201811 linking aortic plaque and liver disease. We will 
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now investigate the therapeutic potential of Lipoxin A4 on lipid-rich atherosclerotic 
plaques in cholesterol fed rabbits and its effect on the progression of NAFL to NASH.  
 
Methods  
In vivo magnetic resonance imaging (MRI) measured aortic atherosclerotic inflammation 
(with plaque Gd-enhancement), plaque size (vessel wall area), and composition, within 
rabbits fed normal chow or a 1% cholesterol-enriched diet. Biomarkers in the blood were 
monitored in the rabbits, with follow-up by histology, which included Masson’s 
trichrome staining. Light Microscopy was used for liver imaging. Ex vivo MRI, T1W 
imaging was used to quantify VWA (vessel wall area), with Image J programming. 
 
Results  
Cholesterol-fed rabbits with and without aortic injury developed hypercholesterolemia, 
NAFL, and atherosclerotic plaques in the aorta. Elevated plasma gamma-glutamyl 
transferase (GGT; p =0.014) and the ratio of liver enzymes aspartate and alanine 
aminotransferases (AST/ALT; p = 0.033) confirmed the progression of steatosis to non-
alcoholic steatohepatitis (NASH).  Histological images showed less fibrosis in those 
rabbits fed 1% CHOL diet with injury treated with LipoxinA4, when compared to 1% 
CHOL diet and injury alone. The plasma biomarkers showed a decrease in cholesterol 
(79%) and triglycerides (49.9%) in those rabbits given LXA4 therapy. The LXA4 treated 
1% CHOL diet with injury group showed a marked decrease in the aorta vessel wall area 
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when compared to the 1% CHOL diet with injury, without treatment; as seen in ex vivo, 
MRI T1W imaging. 
Conclusion 
Lipoxin implementation in cholesterol fed rabbits that have localized regions of highly 
inflamed aortic atherosclerotic plaques, may contribute to the attenuation on the 
progression of NAFL to NASH as seen in histology and plasma biomarkers including; 
cholesterol and triglycerides. Lipoxin as a therapeutic has an effect on treating 
atherosclerotic plaques and attenuating atherosclerosis progression. 
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INTRODUCTION 
Non-Alcoholic Fatty Liver Disease and Steatohepatitis 
 Non-alcoholic fatty liver disease (NAFLD) is found in patients who are not 
considered alcoholic; it causes liver damage.24  NAFLD made up of a spectrum of stages 
from simple steatosis to inflammation associated fibrosis and finally cirrhosis.24 Steatosis 
is the infiltration of liver cells with fat, associated with disturbance of metabolism.26  
Non-Alcoholic Steatohepatitis (NASH) develops in patients with at least one of the 
following risk factors: obesity, dyslipidemia, and glucose intolerance.26 The advancement 
of steatosis in NAFL leads to NASH; it is often seen together with fibrosis and, at some 
point, becomes irreversible with subsequent progressing to cirrhosis.27  Fibrosis is the 
encapsulation or replacement of injured tissue by a collagenous scar. Liver fibrosis 
results from the perpetuation of the normal wound healing response, which results in an 
abnormal development of prolonged fibrogenesis (connective tissue production and 
deposition). Cirrhosis is an advanced stage of liver fibrosis that includes alteration of the 
hepatic vasculature.28 
Steatosis can result from hepatic triglyceride accumulation. Possible mechanisms 
for steatosis include decreased oxidation of fatty acids and increased free fatty acids 
being delivered to the liver, which can cause reduced synthesis of very low density 
lipoprotein (VLDL) and increased hepatic triglyceride synthesis.29 Inflammation may 
result from lipid peroxidative damage to cell membranes. These changes can stimulate 
hepatic stellate cells, resulting in fibrosis.29 
 2 
The accumulation of hepatic fat is associated with hepatic inflammation, which 
increases the risk of liver disease; cirrhosis, hepatic decompensation (liver failure) and/or 
hepatocelluar carcinoma.24 The prevalence of NAFL in the global population is around 
25% and in the presence of obesity, as high as 51%.25 
 
Rabbit Model of Atherosclerosis 
 Rabbit studies have been used to discover novel aspects of cardiovascular disease 
relevant to humans, including the discovery of the role of nitric oxide and the role of 
vascular inflammation.22 Cholesterol-fed rabbits can develop plaques that exhibit 
similarities to human coronary and carotid plaques, which makes them useful as a pre-
clinical model.2  The rabbit model we used, replicates many features of human 
cardiovascular disease, including thrombosis as seen in the human arteries.18  
Our model applies pharmacological triggering to test the vulnerability of 
advanced plaque disruption and thrombosis with Russell viper venom and histamine, 
which combines  activation of coagulation factor Xa and Va and vasoconstriction with 
histamine to stimulate an acute event that can lead to myocardial infarction.18 The 
development of vulnerable plaques can be sped up with the introduction of balloon de-
endothelialization.18  An advantage of the rabbit model is that thrombosis can be 
experimentally controlled, which allows for the study of aortic plaques with noninvasive 
in-vivo MRI and other invasive methods like ex-vivo MRI done after aortic excision.18 
Plaque rupture is characterized by a necrotic core with a overlying highly inflamed thin 
fibrous cap infiltrated by macrophages. The vessel wall is also highly inflamed and has 
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monocyte/neutrophil/macrophage/leukocyte infiltration.23 A recent study showed that 
oral inflammation with Porphyromonas gingivalis exposure exacerbated aortic 
atherosclerosis and systemic inflammation in cholesterol fed rabbits.21 More recently 
Taylor et. al discovered that cholesterol-fed rabbits with induced vascular endothelial 
injury had more inflamed aortic plaques  and  NAFL with fibrosis, suggesting that the 
advanced aortic plaque inflammation had a systemic effect.11 
Lipoxin and Resolution of Inflammation 
 The role of inflammation and some of the underlying mechanisms that contribute 
to atherogenesis have been illuminated by recent studies. An exciting new area of focus 
with broad implications is the linkage inflammation with other chronic diseases, which is 
stimulating greater recognition of nutrition and natural mechanisms of homeostasis.  A 
prolonged nutrient excess of some nutrients results in chronic activation of the immune 
response and associated inflammation.1  
A therapeutic strategy that has the potential overcome chronic inflammation and 
disease is the use of naturally produced specialized pro-resolving mediators (SPMs). 
Cellular and plasma levels of SPMs vary, and chronically low levels of SPMs may 
predispose the progression of chronic vascular inflammation and vulnerability to 
coronary atherosclerosis and thrombosis.14 An example of one such molecule is lipoxin 
which is secreted by immune cells such as neutrophils and macrophages.6  Lipoxins are 
products of the arachidonic acid pathway, and can be stimulated by aspirin treatment as 
described by Serhan et al.7 Endogenous biosynthesis of LXA4 (Lipoxin A4) occurs 
through the interaction of leukocytes with epithelium, endothelium or platelets.7  Lipoxins 
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act at specific GPCRs (G protein-coupled receptor) as agonists to regulate cellular 
responses related to inflammation and resolution.7 Lipoxin binds to GPCR ALX/Formyl 
peptidyl receptor; which prevents binding of other pro-inflammatory ligands like SAA 
(serum amyloid A) and that triggers a wide range of cytoplasmic signaling cascades, as 
schematically illustrated by Chandrasekharan et al, in Figure 1.8  Lipoxins resolve 
inflammation by activating the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) 
and AKT pathways in macrophages, which increases the life span of the macrophage.8 
Lipoxin controls synthesis and release of pro-inflammatory cytokines by increasing the 
mRNA level of suppressors of cytokine signaling and preventing the transcription of 
inflammatory cytokines like IL-8 by inhibiting NFκB and AP-1.8 
 Neutrophils are a key part of the innate immune response, and lipoxins stimulate 
migration of neutrophils to the site of inflammation by increasing their cytosolic calcium 
(Ca2+) levels.9 The increase in calcium promotes cytoskeleton assembly which aids in 
extension of neutrophil pseudopods, making transendothelial migration easier.10 
Macrophages are recruited to the site of infection after neutrophils.8 Lipoxins also 
promote resolution of inflammation by delaying the apoptosis of macrophages.8 Lipoxins 
stimulate activation of the PI3K/Akt and ERK/nuclear factor like 2 (Nrf2) pathways that 
have a role in the inhibition of apoptosis in macrophages.12  T-cell secreted cytokines, 
such as tumor necrosis factor alpha (TNFα) which promotes inflammation can be 
inhibited by lipoxin. 13 
 Lipoxins also help prevent tissue injury by inhibiting the formation of 
peroxonitrite anion (ONOO) at the site of inflammation.16 Peroxonitrite interacts with 
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lipids, DNA, and proteins through direct oxidative reactions or indirect, radical-mediated 
mechanisms. 15 These reactions trigger cellular responses that can be subtle variations of 
cell signaling to damaging oxidative injury, committing cells to necrosis or apoptosis. 15 
 Lipoxin also attenuates the accumulation of nuclear factor κB (NFκB) and 
activator protein-1 (AP-1) in the nucleus, which consequently reduces IL-8 production. 
Inhibiting IL-8 secretion also reduces neutrophil accumulation and activation.17 
Therefore, specialized pro-resolving mediators like lipoxins may provide new 
possibilities to design novel “resolution-targeted” therapy, which could effectively 
control inflammation. 
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Figure 2. The Effect of Lipoxins on various transcription factors and cytoplasmic 
signalling cascades. (Lipoxins: nature’s way to resolve inflammation, Chandrasekharan 
et.al)8: Lipoxin modulates various transcription factors such as nuclear factor κB, 
activator protein-1, nerve growth factor-regulated factor 1A binding protein 1, and 
peroxisome proliferator activated receptor γ and control the expression of many 
inflammatory genes.8 
 
Abbreviations: AP-1, activator protein-1; DAG, diacyl-glycerol; EGR1, early growth 
response 1 gene; ERK, extracellular signal-regulated kinase; IL-8, interleukin 8; IP3, 
inositol triphosphate; JAK, Janus kinase; MEK, mitogen-activated protein kinase kinase; 
MPO, myeloperoxidase; mTOR, mammalian target of rapamycin; NAB1, NGFIA 
binding protein 1; NFκB, Nuclear factor κB; Nrf2, nuclear factor like 2; ONOO, 
peroxonitrite anion; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PLD, 
phospholipase D; PPAR, peroxisome proliferator activated receptor; SAA, serum 
amyloid A; TNFα, tumor necrosis factor alpha; SOCS, suppressors of cytokine signaling; 
PIPP, polyisoprenyl phosphate. 
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METHODS  
 
 Rabbit model of atherosclerosis 
 The methodology in this thesis work is a continuation of the study done by Taylor 
et. al in 2018.11 Female and male New Zealand White rabbits were fed normal chow and 
a 1.0% CHOL containing chow diet for a course of three months (Table 1 includes all of 
the study groups and abbreviations). One of the study groups was 1% CHOL + injury; 
N=4. In this group we induced atherosclerotic lesions with the 1% CHOL diet (TestDiet, 
Saint Louis, MO) in combination with endothelial cell injury via a balloon catheter 
procedure during general anesthesia (acepromazine, 0.75 mg/kg; ketamine, 35 mg/kg; 
xylazine, 2.5 mg/kg for each rabbit).11  The second group (N=3) was treated with  LXA4 
(8 micrograms 3X per week, for a period of 4 weeks) . A Control group (Normal diet) 
was fed a normal chow and not subjected to balloon injury (N=3; female). The normal 
diet consisted of a chow with 16.5% protein, 41% carbohydrates, 22.5% fiber, 2% fat. 
The 1% CHOL diet consisted of a chow that included 10,000 ppm cholesterol, 14.4% 
protein, 42.8% carbohydrates, 23.7% fiber, 2.4% fat by weight.11 The remaining mass 
consisted of vitamins, minerals, ash and moisture.11 
 We induced plaque formation in the aorta and tested whether it formed a luminal 
thrombus in both 1%CHOL  fed groups with  injury.11  We used the standard 
pharmacological procedure that from our past studies of the rabbit model of human 
atherosclerosis 3,4,  At the end of the three months, intraperitoneal injections (two times, 
separated by 48 hours) of coagulation cascade factor-X activating enzyme isolated from 
Russell's Viper Venom (RVV-X 0.15 mg/kg IP; Enzyme Research, South Bend, IN) 
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followed by histamine injection (0.02 mg/kg IV; Sigma Aldrich, St. Louis, Mo) after 30 
min were used to trigger rupture of vulnerable plaques.11   
 At the end of the 2 months, we administered a dosage of Lipoxin orally 8 micrograms 3X 
per week, for a period of 4 weeks to the 1% CHOL + Injury + LXA4 group. Timeline of 
the procedure included 8 weeks of 1% CHOL feeding in the CHOL-fed experimental 
groups for 8 weeks, followed by 4 weeks of normal chow feeding. For the LXA4 group, 
the treatment was given for a period of 4 weeks between week 8 and week 12 (can be 
seen in Figure 2).  
 
Serial magnetic resonance imaging (MRI) of aortic plaque  
 Assessment of the aorta in each rabbit for atherosclerosis was done by  in vivo 
MRI using a Philips Achieva 3T scanner with a 16 channel TR knee coil under general 
anesthesia and free breathing conditions.11 The MRI protocol included T1-weighted 
(T1W) and T2-weighted (T2W) imaging substituted with non-gated 3D black-blood 
sequences repeated at the end of the second and third months.11 
 In excised aortas high field MRI (11.7T; Bruker Biospin Corporation, Billerica, 
MA) was used to study sliced aortic segments that were rinsed in cold saline, fixed in 
10% neutral buffered formalin, and then placed in MR-signal inert fomblin oil (Sigma 
Aldrich).11 The fomblin oil suppresses background signal, providing high signal-to-noise 
proportion during visualization of the tissue.11 Aorta segments were stored in an ice-water 
bath and were equilibrated to room temperature before the ex vivo MRI protocol.11 All 
experiments were conducted with high resolution T1W imaging (28 μm2 in plane 
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resolution with 500 μm slice thickness).11 Diffusion-weighted MRI (DW-MRI; 39 μm2 in 
plane resolution with 500 μm slice thickness with a diffusion-weighting B value of 3,000 
s/mm2). The diffusion-weighting B value was selected and optimized based on the 
protocol developed by Qiao et al., for ex vivo visualization of cholesteryl esters in human 
and rabbit plaques.18,19,11  
Thrombus detection 
At the end of the three-month experiment (Figure 1), thrombus formation was measured 
in ImageJ (NIH, Bethesda, MD) by comparing of matched corresponding regions in the 
MR images (pre- and post-contrast T1W images) obtained before and after triggering.11  
Plasma biomarkers 
Prior to MRI scans, blood was collected (total volumes per draw of 2-4 ml) in heparin 
blood collection tubes for quantification of liver enzymes and lipids (mg/dL). 11 The 
biomarker analysis included measurements of the liver enzymes including; alanine 
aminotransferase (AST), aspartate aminotransferase (ALT), and gammaglutamyl 
transferase (GGT). The ratio of AST and ALT, is called the De Ritis ratio, was used to 
assess liver damage in NASH.20 Other biomarkers that we assessed were total plasma 
triglycerides and plasma free CHOL. 11 All blood biomarkers were measured by the 
Abbott Piccolo Xpress Analyzer (Abbott, Chicago, IL).11  
Histology   
 The liver was fixed with formalin and paraffin embedded. The liver sections were 
stained with Masson’s Trichrome.11 Images of the liver post mortem were taken. 
Masson’s trichrome revealed fibrotic areas that stained blue, these areas were quantified 
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after microscopic imaging and in multiple fields of view at the same magnification with 
ImageJ software using color threshold to quantify liver fibrosis.11 Masson’s trichrome 
stain is the most common histological method applied to the liver. The stain imparts a 
blue color to collagen against a red background of hepatocytes and other structure. It 
stains type 1 collagen, that is present in portal tract and vessel walls. It highlights the 
presence and distribution of fibrosis as a result of liver injury. It is used for classifying 
stages of liver disease, and helps to delineate patterns of injury, such as the perisinusoidal 
fibrosis associated with steatohepatitis.30 
Statistical analysis 
 Statistical comparison was carried out on data derived from 1% CHOL + injury, 
1% CHOL + injury + LXA4, and normal diet rabbit groups. In addition to comparisons 
between groups at study time points, baseline and longitudinal measurements were 
included where possible.11 Two-sample student’s t-test for the mean difference per rabbit, 
one-sided or one sample t-test for comparison with baseline reading was carried out in 
Excel (Microsoft Corporation, Redmond,WA).11  
Table 1. The rabbit groups used in this study. 
Groups used in this study Abbreviation 
Normal diet + no injury  Normal diet 
1% cholesterol diet + endothelial 
injury 
1% CHOL + injury 
1% cholesterol diet + endothelial 
injury + Lipoxin A4 
1% CHOL + injury + LXA4 
*Abbreviation denotes the abbreviated names used in this study 
 
 
 11 
 
 
 
 
 
Figure 2: Timeline of Protocol, Including feeding, injury and treatment in all 3 
groups.  
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RESULTS 
 
 
Plasma Biomarkers: 
 Liver enzyme levels of ALT, AST, and GGT confirmed the presence of NAFL. A 
significant increase in liver enzymes from baseline levels (Table 2; Change in liver 
enzymes in plasma with 1% CHOL diet and endothelial injury) was observed in the blood 
of the CHOL-fed + injury rabbits. Baseline readings are defined as blood plasma samples 
obtained prior to initiation of 1% CHOL diet. Readings in blood were also obtained at 
three months after pharmacologic triggering. GGT, AST, and ALT were all increased by 
164%, 356%, and 158%. The ratio of AST to ALT increased from 0.63 to 1.11; a 176% 
increase and this effect is substantial. 
At the end of the second month of the preparation protocol, the 1% CHOL diet 
was switched to normal diet, as in our standard procedure, and LXA4 was initiated in the 
therapy group. The blood cholesterol and triglycerides were measured at 2 month and 3 
months. At the 2-month point, (prior to any therapy) both groups that were given the 1% 
CHOL diet and injury had high cholesterol and triglyceride levels (812.8, 62 respectively 
in 1% CHOL diet + injury) and (2065, 82.3 respectively in CHOL diet + injury + LXA4). 
At the beginning of the 3rd month, the rabbits were all placed on a normal diet. After 3 
months, when the therapy group had undergone lipoxin A4 treatment, the triglycerides 
and cholesterol were measured and compared. After switching to a normal diet, at the end 
of 3 months, the without therapy group (1% CHOL diet+ injury) had a 39.5% decrease in 
cholesterol and had a increase in triglycerides. The therapy group (1% CHOL diet+ 
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injury+ LXA4) showed a 79.8% decrease in cholesterol and 49.9% decrease in 
triglyceride from the implementation of lipoxin treatment. There were much higher lipids 
in the therapy group before the treatment, this was most likely due to the cholesterol diet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
 
Liver Enzyme 
Biomarker 
Baseline After 1% CHOL + 
injury 
P-value 
GGT (U/L) 6.3 ± 0.5 10.3 ± 1.3 
 
0.014 
 
 
AST/ALT ratio 0.63 ± 0.12 1.11 ± 0.18 
 
0.033 
 
Table 2: Change in liver enzymes in plasma with 1% CHOL diet and endothelial 
injury (N=4). Readings from blood plasma were compared in 1% CHOL + injury rabbits 
to baseline readings. Baseline readings are defined as blood plasma samples obtained 
prior to initiation of 1% CHOL diet. Readings in blood were also obtained at three 
months after pharmacologic triggering. The P-value displayed was obtained from the 
student’s t-test comparing the baseline and after trigger readings. 
 
 
 
 
No Therapy: 1% CHOL diet+ 
injury (N=4) 
Therapy: 1% CHOL diet + injury 
+ LXA4 (N=3) 
 2 months 3 months % decrease 2 months 3 months % decrease 
Cholesterol 812.8 467.5 39.6%* 2065.0 485.7 79.8% **,† 
Triglyceride 62.0 89.7 increase 82.3 43.0 49.9%** 
 
Table 3 Blood lipids before and after four weeks of LXA4 therapy. The * indicates a 
p-value is less than 0.05 and ** p-value less than 0.005 using a one-sided t-test 
comparing two- and three-months blood draws from the same group. † indicates p-value 
less than 0.05 by two-sided t-test when comparing the no therapy and therapy groups. 
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Histology  
 
Masson’s trichrome staining of the liver and whole liver images 
Masson’s trichrome stain imparts a blue color to collagen against a red background of 
hepatocytes and other morphological structures. It stains type 1 collagen blue, which is 
present in portal tract and vessel walls.  As shown in Figure 3 the normal diet rabbit 
shows normal distribution of collagen fibers, stained dark purple, around a portal tract. 
1% CHOL+ injury shows a marked increase in blue staining, showing an increase in 
collagen fibers around the blood vessels in the portal tract.  1% CHOL+ injury + LXA4 
shows much less blue uptake in the liver, showing a lower distribution of collagen fibers 
around a portal tract, when compared to the cholesterol + injury group with no treatment.  
Whole liver photographic images (Figure 3) taken post mortem dramatically illustrate 
liver disease and effective therapy by LXA4. The normal diet rabbit liver is lean with 
good hepatic circulation and a bright red color. With CHOL feeding, color changed to a 
paler pink color, meaning decreased hepatic circulation. In addition, the rabbit liver of the 
1% CHOL + Injury + LXA4 is a pale color, however has less color loss when compared 
to the no treatment rabbit (1% CHOL + injury). See figure 3 for complete details.  
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Figure 3 Trichrome Staining Microscope Liver and Whole Liver Images 
Masson’s Trichrome staining of collagen within the liver tissue. Normal diet shows 
normal distribution of collagen fibers, stained dark purple, around a portal tract. 1% 
CHOL+ injury shows marked increase in blue staining, therefore an increase in collagen 
fibers around the blood vessels in the portal tract.  1% CHOL+ injury + LXA4 shows less 
blue uptake in the liver, so a lower distribution of collagen fibers around a portal tract. 
The whole liver images are taken post mortem; Normal diet rabbit liver is lean with 
bright red color. 1% CHOL + injury rabbit liver shows lots of fibrosis and decreased 
hepatic circulation, is a paler pink color. 1% CHOL + Injury + LXA4 has some fibrosis 
and is less pale and has less much fibrosis than the no treatment rabbit (1% CHOL + 
injury).  
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Quantification of Liver Fibrosis 
 
The quantification of trichrome staining revealed how much of the liver area (%) took up 
masson’s trichrome, with the color blue reflecting the amount of collagen in the liver. 
Those areas with greater collagen meant greater fibrosis (Figure 3). Figure 4 shows a bar 
graph quantification. The 1% CHOL diet + injury group had the most trichrome staining 
(~9%), and the normal diet group had the least amount of trichrome staining (<2%). The 
1% CHOL+ injury+ Lipoxin A4 therapy group showed a marked decrease when 
compared to the experimental group with no treatment, with ~3% staining of the liver 
area. 
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Figure 4 Quantification of Liver Fibrosis. Trichrome staining revealed how much of 
masson’s trichrome was taken up in the liver; areas that took up more reflected higher 
collagen and fibrosis in the liver. Those areas with greater collagen meant greater 
trichrome staining. 1% CHOL diet + injury group had the most trichrome staining (*p 
<0.05) compared to normal diet). The normal diet group had the least amount of 
trichrome staining. The 1% CHOL+ injury+ Lipoxin A4 therapy group showed a marked 
decrease when compared to the 1% CHOL+ injury group with no treatment (#p <0.05 
compared to 1% CHOL + injury).  
 
Aorta vessel wall area (mm²) 
The normal diet group had an overall smaller aorta vessel wall area than injury and 
Lipoxin treated groups. 1% CHOL diet + injury group had the highest aorta vessel wall 
area. The LXA4 treated groups had lower aorta vessel wall areas when compared to the 
1% CHOL + injury with no treatment. The 1% CHOL diet + injury group had an overall 
larger aorta vessel wall area (mm.) than normal group (*p<0.05 compared to normal). 
The LXA4 treated group had a lower aorta vessel wall area when compared to the 1% 
CHOL + injury with no treatment (# p < 0.05 compared to injury). 
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Figure 4 Quantification of Liver Fibrosis. Trichrome staining revealed how much of 
masson’s trichrome was taken up in the liver; areas that took up more reflected higher 
collagen and fibrosis in the liver. Those areas with greater collagen meant greater 
trichrome staining. 1% CHOL diet + injury group had the most trichrome staining (*p 
<0.05) compared to normal diet). The normal diet group had the least amount of 
trichrome staining. The 1% CHOL+ injury+ Lipoxin A4 therapy group showed a marked 
d crease when compared to the 1% CHOL+ injury group with no treatment (#p <0.05 
compared to 1% CHOL + injury). 
 
Aorta vessel wall area (mm ) 
The normal diet group had an overall smaller aorta vessel wall area than injury and 
Lipoxin treated groups. 1% CHOL diet + injury group had the highest aorta vessel wall 
area. The LXA4 treated groups had lower aorta vessel wall areas when compared to the 
1% CHOL + injury with no treatment. The 1% CHOL diet + injury group had an overall 
larger aorta vessel wall area (mm ) than normal group (*p<0.05 compared to normal). 
The LXA4 treated group had a lower aorta vessel wall area when compared to the 1% 
CHOL + injury with no treatment (# p < 0.05 compared to injury). 
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    Normal  Injury         LXA4  
 
Figure 5 Aorta vessel wall area with treatment (ex vivo). Normal diet group is labelled 
as normal (N=3). 1% CHOL diet + injury group is labelled as injury (N=4). 1% CHOL 
diet + injury group is labelled as injury (N=4). 1% CHOL diet + injury + LXA4 group is 
labelled as LXA4 (N=3). The 1% CHOL diet + injury group had an overall larger aorta 
vessel wall area (mm²) than normal group (*p <0.05 compared to normal). 1% CHOL 
diet + injury group had the highest aorta vessel wall area. The LXA4 treated groups had a 
lower aorta vessel wall area when compared to the 1% CHOL + injury with no 
treatment(# p < 0.05 compared to injury). 
 
 
. 
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DISCUSSION 
 
 The focus of this study was to investigate the therapeutic potential of 
Lipoxin A4 on the progression of fibrosis in NAFL, in a rabbit model of atherosclerosis. 
To confirm the presence of NAFL and effects of treatment we measured at liver enzymes 
in blood samples. We used the De Ritis20 ratio to assess the liver damage, 
 As shown in our plasma biomarkers, cholesterol fed rabbits treated with LXA4 
had a marked decrease in triglycerides and free blood cholesterol when compared to 
those cholesterol fed rabbits with no treatment. In a large clinical cohort study, diabetic 
patients with advanced fibrosis (n=204) had the mean AST/ALT ratio of 0.98, advanced 
fibrosis in this study was defined by histological bridging fibrosis or cirrhosis.31 We also 
measured GGT, which also significantly increased after the 1% CHOL diet and injury. 
GGT is a measure of liver function because it is responsible for the extracellular 
catabolism of the antioxidant glutathione and is suspected to be important in chronic 
inflammation and systemic oxidative demand.11 In future directions of study, the GGT 
levels could be compared prior and post immunoresolvent treatment in the atherosclerosis 
rabbit model.  
 Rabbit vasculature is similar to humans, and the diameter of the aorta is similar 
that to average diameter of human coronaries, making the rabbit model of atherosclerosis 
relevant for clinical applications. Rabbits in this study developed plaques similar to 
humans. In addition, blood cholesterol and triglycerides were elevated during cholesterol 
feeding and lowered after return to normal chow in the third month. The lipoxin therapy 
in 1% CHOL diet + injury + LXA4 resulted in a larger 79.8% decrease in cholesterol and 
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49.9% decrease in triglyceride. The treatment of Lipoxin indicates that the 
immuoresolvent can decrease free blood cholesterol and triglycerides. The decrease in 
these plasma biomarkers is clinically significant. In recent studies, the presence of 
hypercholesterolaemia was investigated; it was shown that hypercholesterolaemia lead to 
cholesterol accumulation in macrophages and other immune cells, which promotes 
inflammatory responses.32 Therefore, a decrease in cholesterol and triglycerides 
systemically would lead to decreased systemic inflammation, and could attenuate the 
progression of a inflammatory pathological disease. SPM’s like LXA4, shown in our 
study; lead to a decrease in triglycerides and cholesterol, which has the implication that 
when used as a therapeutic could lower overall systemic inflammation.  
There was a marked change in the size of the aorta vessel wall area with induction 
of atherosclerosis with balloon injury and cholesterol feeding. In our study, lipoxin 
demonstrated a cardio-protective effect; the treatment of LXA4 decreased the size of 
aorta vessel wall area in those rabbits with plaques established from a cholesterol diet and 
vascular endothelial injury. Lipoxins attenuate processes associated with atheroscleortic 
plaque formation including; neutrophil recruitment, activation and neutrophil 
extracellular traps formation. Lipoxins also enhance resolution by enhancing 
efferocytosis.36 From our past studies with a similar immunoresolvent (Resolvin E1), we 
showed that atherosclerosis can be attenuated from SPM therapeutic treatment 
effectively. SPM therapy is simpler and safer than implementing other invasive 
procedures.32 A SPM therapeutic approach would likely have few side effects and 
provide long-term safety with respect to atherosclerosis and CVD. 
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The LXA4 therapy had a beneficial effect on the fibrosis of the liver. Our study 
showed that in treatment of LXA4 reduced fibrosis compared to livers of untreated 
rabbits. Masson’s trichrome stain is a common histology special stain for liver and 
cardiac biopsies, they conveniently highlight the amount and distribution of fibrosis.33 
Because of background staining, trichrome stains also allow easy evaluation of liver 
architecture.33 1% CHOL+ injury shows marked increase in blue staining when compared 
to the normal diet group. The 1% CHOL + injury group showed an increase in collagen 
fibers around the blood vessels in the portal tract (figure 3).  1% CHOL+ injury + LXA4 
shows less blue stain uptake in the liver, so a lower distribution of collagen fibers around 
a portal tract. Those rabbits that were given the 1% CHOL and the endothelial injury had 
a significant amount of collagen fibers around the portal tract, indicating that there was 
severe fibrosis. The rabbits treated with LXA4 had less of fibrosis, although there was 
some blue staining, there was substantially less collagen deposition in the liver (see 
figure 3).  From other studies, it has been shown that other SPMs (RvE1, Protectin D1, 
and D-series Rvs) attenuate obesity-induced liver disease.34 Recent data has highlighted a 
protective effect of Lipoxins and other arachidonate-derived mediators in cardiovascular 
disease associated with increased reverse cholesterol transfer.35 From our study, lipoxins 
attenuated the fibrosis of the liver; showing a portal tract that looked closer to normal 
than those cholesterol fed rabbits with injury and without treatment.   
Collectively, the results from this study shows that LXA4 plays a role in 
modulating hepatic inflammation and fibrogenesis during NASH progression. LXA4 
demonstrates the potential of using SPM’s to attenuate obesity-induced pathologies.   
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The use of the rabbit model is advantageous for studying human disease instead 
of persons directly. Rabbits have served as a primary experimental model for some 
human infectious diseases, because of their susceptibility to infection and the similarity 
of pathogenesis to that in humans.37 Rabbit vasculature is similar to humans, and the 
diameter of the aorta is similar that to average diameter of human coronaries, making the 
rabbit model of clinically ideal for cardiovascular research.22 Studying the liver is 
challenging; studies are limited by lack of tissue except for liver biopsies, which are 
rarely performed and autopsies. The use of liver MRI is also less well developed than 
vascular MRI.21 Studies correlating progression and regression are of liver disease is 
almost impossible.37 The induction of liver disease in human for controlled experiments is 
unethical. There is a rapid development of rabbit genomics, proteomics, transgenic and 
knockout lines, and rabbit-specific reagents, the use of rabbits as experimental models in 
biomedical research will likely increase.37 The rabbit model has the ability to bridge the 
gap between rodents and the large animal models often required for preclinical and 
translational research.37 
The future directions for this study could include investigating the effects of LXA4 on 
immunological biomarkers like white blood cells, neutrophils, macrophages. Future 
studies of the pro-resolving effects of SPMs are to be investigated in other inflammatory 
pathologies including rheumatoid arthritis and psoriasis. 
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